Pfizer, Innovent GLP-1 drugs added to China national insurance for diabetes
Pfizer and Innovent Biologics' GLP-1 drugs will be added to China's national health insurance scheme from January 1, 2024, for type 2 diabetes treatment, according to the National Healthcare Security Administration. This move challenges Danish rival Novo Nordisk, whose Ozempic drug saw a 7% sales decline in the greater China region in 2025. Inclusion in the reimbursement list increases drug availability but may lead to lower prices.
How this was made

The 30-second read
Why it matters
The inclusion signals a sizable new patient base for Pfizer, potentially increasing sales but also introducing price pressure due to negotiated reimbursement rates.
Market read
First‑time coverage of Pfizer's GLP‑1 drug in China could boost its international sales pipeline and affect sector dynamics.
What to watch
Regulatory approval timelines, competition from Novo Nordisk and Eli Lilly, and potential supply constraints.
Background
China's National Healthcare Security Administration expands its insurance coverage to include new GLP‑1 drugs from Pfizer and Innovent, joining existing coverage for Novo Nordisk and Eli Lilly products.
Ticker impact
Pfizer's ecnoglutide added to China's national insurance list, opening a large market for its GLP‑1 drug.
upward pressure as investors price in potential revenue growth from China market
Policy inclusion typically expands patient access and drives higher volumes, though pricing may be lower.
Market effects
May lift broader GLP‑1 and diabetes‑treatment sector as peers gain exposure to Chinese market.
Adds upside bias to US pharma exposure in China, could benefit other multinational drug makers.
Highlights China's expanding role in global pharma reimbursement policies.
Counterpoint
Price impact may be muted if reimbursement comes with steep price cuts, limiting margin expansion.
Key entities
- companyPfizer
US‑based pharmaceutical giant with GLP‑1 drug ecnoglutide.
- companyInnovent Biologics
Chinese biotech developer of mazdutide.
- government_agencyNational Healthcare Security Administration
Chinese regulator responsible for the national insurance list.

